FeLV p27 antigen detection: comparing two ELISA assays in feline samples
Veterinary medicine international · 2025
In plain language
The study compared two tests for a FeLV protein, the p27 antigen, using 112 blood samples from cats tested in the laboratory. The reference test classified 42 samples as positive and 70 as negative, but whether those classifications reflected infection status was not independently checked. The cats’ clinical conditions were unknown, and the evaluation had several limitations. The study does not establish whether the results can identify tumors caused by FeLV or predict the development of cancer.
Scientific detail
The study published in Veterinary medicine international in 2025 (doi: 10.1155/vmi/9914340) evaluated FeLVCHECK Ag ELISA against ViraCHEK/FeLV ELISA in vitro for FeLV p27 antigen detection. It analyzed 112 feline serum or plasma samples, classified by the reference ELISA as 42 positive and 70 negative. The number of individual cats was not reported. This controlled assay comparison is classified as level B evidence in the source object; it was not a controlled clinical outcome study. Positive and negative categories were defined by the comparator, not by an independent determination of infection status.
Validation reused the samples employed to select the cut-off. The reference assay was also an antigen ELISA, and discordant results were not independently verified. The investigators acknowledged that they did not conduct extensive cross-reactivity studies, partly because representative samples were unavailable. This limitation, classified as level C evidence, does not demonstrate that any particular cross-reactivity caused the observed discordances; mechanisms described in earlier publications were not established for this assay.
Information on the cats’ clinical conditions was unavailable, a limitation classified as level C evidence. The intention to include a broad range of cases does not demonstrate that lymphoma, leukemia, or specific FeLV infection states were represented. Stability testing used a single batch. In addition, the supplied text contains an omitted passage and does not include the underlying supporting-information datasets.
The evidence comes directly from feline samples and concerns detection of an infection-associated antigen, not an investigation of lymphoma, leukemia, or oncogenic mechanisms. The study does not establish whether antigen results identify FeLV-driven tumors, predict neoplastic progression, or distinguish tumor subtypes. Its discussion of insertional mutagenesis draws on prior literature and is not a new experimental finding.
What we know
FeLVCHECK Ag ELISA was compared in vitro with ViraCHEK/FeLV ELISA using 112 feline samples; the comparator classified 42 as positive and 70 as negative. This is direct evidence about p27 antigen detection in cat samples, limited by reuse of samples for cut-off selection and validation, the absence of independent verification of discordances, missing clinical information, and incomplete cross-reactivity assessment.
What we don't know
The number of individual cats contributing samples was not reported, and their clinical conditions were unknown. Infection status was not independently established to define the comparator categories, and discordant results were not independently verified. Whether any particular cross-reactivity explained those discordances was not established. Stability testing with a single batch does not establish stability across batches. Nor does the study establish whether results identify FeLV-driven tumors, predict neoplastic progression, or distinguish tumor subtypes. The omitted passage and supporting datasets are not available in the supplied material.
Evidence
EvidenceLevel B — Direct experimental evidenceConfidence 100/100
FeLVCHECK Ag ELISA was validated against ViraCHEK/FeLV ELISA using 112 feline sera classified as 42 positive and 70 negative.
Excerpt verified in the source — verbatim, in the source's own language“The new ELISA was validated against the ViraCHEK/FeLV ELISA (Zoetis, NJ, USA) as the reference test by testing 112 feline sera (42 positives and 70 negatives) according to the manufacturer's instructions.”
This is a controlled FeLV-specific laboratory assay comparison using feline specimens, not a controlled clinical outcome study. Positive and negative categories were defined by the comparator assay rather than independently established infection status.
EvidenceLevel C — Preliminary evidenceConfidence 100/100
The investigators did not perform extensive cross-reactivity studies, partly because representative samples were unavailable.
Excerpt verified in the source — verbatim, in the source's own language“In this instance, we have not carried out extensive studies to investigate cross-reactivity reactions, partly because of the lack of available representative samples, hard to collect because they should derive from animals affected by various diseases whose distribution also depends on endemic or seasonal status in different countries.”
This is an acknowledged limitation, not evidence that any particular cross-reactivity caused the observed discordances. Cross-reactivity mechanisms discussed from earlier publications were not established for this assay.
EvidenceLevel C — Preliminary evidenceConfidence 100/100
Clinical-condition information was unavailable for the cats providing the samples.
Excerpt verified in the source — verbatim, in the source's own language“We did not have information about cat's clinical conditions; thus, no sample selection was performed to contemplate the broadest possible cases.”
The authors explicitly report a clinical-characterization limitation. Their intention to include broad cases does not demonstrate coverage of lymphoma, leukemia, or particular FeLV infection states.
Provenance
Source: Feline Leukemia Virus in Cats: A Novel Rapid ELISA Assay for p27 Antigen Detection.
AVA